(News Bulletin 247) – Euroapi plans to invest 50 million euros on its Budapest site in order to meet the growing demand for prostaglandins, substances used in various therapeutic indications.
The manufacturer of active pharmaceutical ingredients indicates that it plans to install new state-of-the-art equipment within the factory, with the objective of doubling its production capacity of prostaglandins by 2027.
According to the group, prostaglandins constitute one of the most dynamic segments of the market today, with annual sales of around five billion euros and an expected annual growth rate of between 5% and 7%. by 2027.
Euroapi stresses that it is today the only Western supplier to have both a complete portfolio of prostaglandins and a fully integrated production site located in Europe.
The project should enable it to reduce its environmental footprint thanks to a modern air treatment system that will reduce the energy consumption of the new workshop.
The production site will also be equipped with solar panels and a fully enclosed waste treatment system.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
